View in EDS

Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.

Saved in:
Bibliographic Details
Title: Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.
Authors: Burmester, Gerd1 (AUTHOR), Trefler, Jakub2 (AUTHOR), Racewicz, Artur3 (AUTHOR), Jaworski, Janusz4 (AUTHOR), Zielińska, Agnieszka5 (AUTHOR), Krogulec, Marek6 (AUTHOR), Jeka, Sławomir7 (AUTHOR), Wojciechowski, Rafał8 (AUTHOR), Kolossa, Katarzyna9 (AUTHOR), Dudek, Anna10 (AUTHOR), Krajewska-Włodarczyk, Magdalena11 (AUTHOR), Hrycaj, Paweł12 (AUTHOR), Klimiuk, Piotr Adrian13 (AUTHOR), Kim, SungHyun14 (AUTHOR), Suh, JeeHye14 (AUTHOR), Yang, GoEun14 (AUTHOR), Kim, YunAh14 (AUTHOR), Jung, YooBin14 (AUTHOR), Park, GaHee14 (AUTHOR), Smolen, Josef S.15 (AUTHOR) josef.smolen@meduniwien.ac.at
Source: Clinical Drug Investigation. Aug2025, Vol. 45 Issue 8, p551-563. 13p.
Database: Academic Search Ultimate
Description
ISSN:11732563
DOI:10.1007/s40261-025-01453-8